Complement and the control of HIV infection: An evolving story

Current Opinion in HIV and AIDS

Volumn 9, Issue 3, 2014, Pages 278-290

  Frank, Michael M ^a   Hester, Christopher ^a   Jiang, Haixiang ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Asialoglycoprotein receptors; complement; innate immune defense; mannose receptors

Indexed keywords

COMPLEMENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PLASMA PROTEIN; VIRUS ENVELOPE PROTEIN; ASIALOGLYCOPROTEIN RECEPTOR; CELL SURFACE RECEPTOR; LECTIN; MANNOSE BINDING LECTIN; MANNOSE RECEPTOR;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN BINDING; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; INNATE IMMUNITY; LIFESPAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS PARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

ASIALOGLYCOPROTEIN RECEPTOR; COMPLEMENT SYSTEM PROTEINS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; LECTINS, C-TYPE; MANNOSE-BINDING LECTINS; RECEPTORS, CELL SURFACE;

EID: 84898545872     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000058     Document Type: Review

References (61)

1. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science 2008; 321:530-532.
2. Johnston MI, Fauci AS. HIV vaccine development-improving on natural immunity. N Engl J Med 2011; 365:873-875.
3. McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10:11-23.
4. Joiner KA, Brown EJ, Frank MM. Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol 1984; 2:461-491.
5. Walport MJ. Complement-first of two parts. N Engl J Med 2001; 344:1058-1066.
6. Walport MJ. Complement-second of two parts. N Engl J Med 2001; 344:1140-1144.
7. Frank MM. Complement. In: Introduction and historical notes. New York: Marcel Decker; 1998.
8. Frank MM. Complement disorders and hereditary angioedema. J Allerg Clin Immunol 2010; 125 (2 Suppl 2):S262-S271.
9. Lambris JD, Muller-Eberhard HJ. The multifunctional role of C3: structural analysis of its interactions with physiological ligands. Mol Immunol 1986; 23:1237-1242.
10. Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement system. Adv Immunol 1996; 61:201-283.
11. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007; 25:619-647.
12. Carroll MC. The complement system in B cell regulation. Mol Immunol 2004; 41:141-146.
13. Carroll M. The complement system in regulation of adaptive immunity. Nat Immunol 2004; 5:981-986.
14. Pangburn MK, Muller-Eberhard HJ. The alternative pathway of complement. Springer Semin Immunopathol 1984; 7:163-192.
15. Jensenius JC. The mannan-binding lectin (MBL) pathway of complement activation: biochemistry, biology and clinical implications. Adv Exp Med Biol 2005; 564:21-22.
16. Degn SE, Jensenius JC, Thiel S. Disease-causing mutations in genes of the complement system. Am J Hum Genet 2011; 88:689-705.
17. Ward PA. Functions of C5a receptors. J Mol Med 2009; 87:375-378.
18. Krych M, Molina H, Atkinson JP. CD35: complement receptor type 1. J Biol Regul Homeost Agents 1999; 13:229-233.
19. Phan TG, Grigorova I, Okada T, Cyster JG. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat Immunol 2007; 8:992-1000.
20. Ochs HD, Nonoyama S, Zhu Q, et al. Regulation of antibody responses: the role of complement and adhesion molecules. Clin Immunol Immunopathol 1993; 67 (3 Pt 2):S33-S40.
21. Chen Z, Koralov SB, Kelsoe G. Regulation of humoral immune responses by CD21/CD35. Immunol Rev 2000; 176:194-204.
22. Burton GF, Masuda A, Heath SL, et al. Follicular dendritic cells (FDC) in retroviral infection: host/pathogen perspectives. Immunol Rev 1997; 156:185-197.
23. Ho J, Moir S, Kulik L, et al. Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J Immunol 2007; 178:6968-6974.
24. Jakubik JJ, Saifuddin M, Takefman DM, Spear GT. B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1. Immunology 1999; 96:612-619.
25. Montefiori DC, Stewart K, Ahearn JM, Zhou J. Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). J Virol 1993; 67:2699-2706.
26. Sohn JH, Bora PS, Suk HJ, et al. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat Med 2003; 9:206-212.
27. Dempsey PW, Allison ME, Akkaraju S, et al. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996; 271:348-350.
28. Frank MM. Complement Deficiencies. Pediatr Clin North Am 2000; 47:1339-1354.
29. Frank MM. Animal models for complement deficiencies. J Clin Immunol 1995; 15 (6 Suppl):113S-121S.
30. Carroll MV, Sim RB. Complement in health and disease. Adv Drug Deliv Rev 2011; 63:965-975.
31. Gonzalez SF, Degn SE, Pitcher LA, et al. Trafficking of B cell antigen in lymph nodes. Annu Rev Immunol 2011; 29:215-233.
32. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun 2010; 34:J276-J286.
33. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Ann Rev Immunol 2004; 22:431-456.
34. Haynes BF, Fleming J, St Clair EW, et al. Cardiolipin polyspecific auto-reactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308:1906-1908.
35. Cinamon G, Zachariah MA, Lam OM, et al. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol 2008; 9:54-62.
36. Datta PK, Rappaport J. HIV and complement: hijacking an immune defense. Biomed Pharmacother 2006; 60:561-568.
37. Stoiber H, Banki Z, Wilflingseder D, Dierich MP. Complement-HIV inter-actions during all steps of viral pathogenesis. Vaccine 2008; 26:3046-3054.
38. Susal C, Kirschfink M, Kropelin M, et al. Complement activation by recombi-nant HIV-1 glycoprotein gp120. J Immunol 1994; 152:6028-6034.
39. Solder BM, Schulz TF, Hengster P, et al. HIV and HIV-infected cells differentially activate the human complement system independent of antibody. Immunol Lett 1989; 22:135-145.
40. Banapour B, Sernatinger J, Levy JA. The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology 1986; 152:268-271.
41. Barouch DH, Stephenson KE, Borducchi EN, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 2013; 155:531-539.
42. Saifuddin M, Ghassemi M, Patki C, et al. Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis. AIDS Res Hum Retroviruses 1994; 10:829-837.
43. Bajtay Z, Speth C, Erdei A, Dierich MP. Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). J Immunol 2004; 173:4775-4778.
44. Ebenbichler CF, Thielens NM, Vornhagen R, et al. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991; 174:1417-1424.
45. Susal C, Kirschfink M, Kropelin M, et al. Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120. Blood 1996; 87:2329-2336.
46. Spear GT, Sullivan BL, Takefman DM, et al. Human immunodeficiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse and guinea-pig sera; activation results in virus neutralization by virolysis. Immunology 1991; 73:377-382.
47. Saifuddin M, Hedayati T, Atkinson JP, et al. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 1997; 78 (Pt 8):1907-1911.
48. Montefiori DC, Cornell RJ, Zhou JY, et al. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 1994; 205:82-92.
49. Ji X, Gewurz H, Spear GT. Mannose binding lectin (MBL) and HIV. Mol Immunol 2005; 42:145-152.
50. Israels J, Scherpbier HJ, Frakking FN, et al. Mannose-binding lectin and the risk of HIV transmission and disease progression in children: a systematic review. Pediatr Infect Dis J 2012; 31:1272-1278.
51. Breukels MA, Zandvoort A, Rijkers GT, et al. Complement dependency of splenic localization of pneumococcal polysaccharide and conjugate vaccines. Scand J Immunol 2005; 61:322-328.
52. Roozendaal R, Mempel TR, Pitcher LA, et al. Conduits mediate transport of low-molecular-weight antigento lymph node follicles. Immunity 2009; 30:264-276.
53. Phan TG, Gray EE, Cyster JG. The microanatomy of B cell activation. Curr Opin Immunol 2009; 21:258-265.
54. Sette A, Grey H, Oseroff C, et al. Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine 2009; 27 (Suppl 6):G21-G26.
55. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105:7552-7557.
56. Frank MM. The reticuloendothelial system and bloodstream clearance. J Lab Clin Med 1993; 122:487-488.
57. Igarashi T, Brown C, Azadegan A, et al. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med 1999; 5:211-216.
58. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-1586.
59. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982; 51:531-554.
60. Arrighi JF, Pion M, Garcia E, et al. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J Exp Med 2004; 200:1279-1288.
61. Bouhlal H, Chomont N, Requena M, et al. Opsonization of HIV with complement enhances infection of dendritic cells and viral transfer to CD4 T cells in a CR3 and DC-SIGN-dependent manner. J Immunol 2007; 178:1086-1095.